Interactions : אינטראקציות

4.5 Interaction with other medicinal products and other forms of interaction
• MAOIs and/or RIMAs: Pseudoephedrine exerts its vasoconstricting properties by stimulating α -adrenergic receptors and displacing noradrenaline from neuronal storage sites. Since monoamine oxidase inhibitors (MAOIs) impede the metabolism of sympathomimetic amines and increase the store of releasable noradrenaline in adrenergic nerve endings, MAOIs may potentiate the pressor effect of pseudoephedrine. This product should not be used in patients taking monoamine inhibitors or within 14 days of stopping treatment as there is an increased risk of hypertensive crisis.
• Moclobemide: Risk of hypertensive crisis.
• Antihypertensives: Because of its pseudoephedrine content, this product may partially reverse the hypotensive action of antihypertensive drugs which interfere with sympathetic activity including bretylium, betanidine, guanethedine, debrisoquine, methyldopa, adrenergic neurone blockers and beta-blockers.
• Cardiac glycosides: Increased risk of dysrhythmias.
• Ergot alkaloids (ergotamine & methysergide): Increased risk of ergotism.
• Appetite suppressants and amphetamine-like psychostimulants: Risk of hypertension.
• Oxytocin: Risk of hypertension.
• Anticholinergic drugs: Enhances effects of anticholinergic drugs (such as Tricyclic antidepressants).
• Anaesthetic agents: Concurrent use with halogenated anaesthetic agents such as chloroform, cyclopropane, halothane, enflurane or isoflurane may provoke or worsen ventricular arrhythmias.